TY - JOUR
T1 - Hematogenous Dissemination of Breast Cancer Cells From Lymph Nodes Is Mediated by Tumor MicroEnvironment of Metastasis Doorways
AU - Coste, Anouchka
AU - Karagiannis, George S.
AU - Wang, Yarong
AU - Xue, Emily A.
AU - Lin, Yu
AU - Skobe, Mihaela
AU - Jones, Joan G.
AU - Oktay, Maja H.
AU - Condeelis, John S.
AU - Entenberg, David
N1 - Funding Information:
This work was supported by the National Cancer Institute and the National Institutes of Health [Grant Numbers:
Funding Information:
The authors would like to thank Deciphera Pharmaceuticals for providing the Tie2 inhibitor, Rebastinib, and Dr. Lalage Wakefield (NCI, National Institutes of Health) for supplying the MDA-MB-231-SORE6-dsCopGFP cell line. Funding. This work was supported by the National Cancer Institute and the National Institutes of Health [Grant Numbers: CA216248, CA100324, CA200561, CA172637, CA237851, and OD019961], the Gruss Lipper Biophotonics Center and its Integrated Imaging Program at the Albert Einstein College of Medicine.
Publisher Copyright:
© Copyright © 2020 Coste, Karagiannis, Wang, Xue, Lin, Skobe, Jones, Oktay, Condeelis and Entenberg.
PY - 2020/10/26
Y1 - 2020/10/26
N2 - In primary breast tumors, cancer cells hematogenously disseminate through doorways in the vasculature composed of three-cell complexes (known as Tumor MicroEnvironment of Metastasis) comprising a perivascular macrophage, a tumor cell overexpressing the actin-regulatory protein Mammalian Enabled (Mena), and an endothelial cell, all in direct physical contact. It has been previously shown that once tumor cells establish lymph node metastases in patients, TMEM doorways form in the metastatic tumor cell nests. However, it has not been established if such lymph node-TMEM doorways actively transit tumor cells into the peripheral circulation and on to tertiary sites. To address this question in this short report, we used a mouse model of lymph node metastasis to demonstrate that TMEM doorways: (1) exist in tumor-positive lymph nodes of mice, (2) are restricted to the blood vascular endothelium, (3) serve as a mechanism for further dissemination to peripheral sites such as to the lungs, and (4) their activity can be abrogated by a pharmaceutical intervention. Our data suggest that cancer cell dissemination via TMEM doorways is a common mechanism of breast cancer cell dissemination to distant sites and thus the pharmacological targeting of TMEM may be necessary, even after resection of the primary tumor, to suppress cancer cell dissemination.
AB - In primary breast tumors, cancer cells hematogenously disseminate through doorways in the vasculature composed of three-cell complexes (known as Tumor MicroEnvironment of Metastasis) comprising a perivascular macrophage, a tumor cell overexpressing the actin-regulatory protein Mammalian Enabled (Mena), and an endothelial cell, all in direct physical contact. It has been previously shown that once tumor cells establish lymph node metastases in patients, TMEM doorways form in the metastatic tumor cell nests. However, it has not been established if such lymph node-TMEM doorways actively transit tumor cells into the peripheral circulation and on to tertiary sites. To address this question in this short report, we used a mouse model of lymph node metastasis to demonstrate that TMEM doorways: (1) exist in tumor-positive lymph nodes of mice, (2) are restricted to the blood vascular endothelium, (3) serve as a mechanism for further dissemination to peripheral sites such as to the lungs, and (4) their activity can be abrogated by a pharmaceutical intervention. Our data suggest that cancer cell dissemination via TMEM doorways is a common mechanism of breast cancer cell dissemination to distant sites and thus the pharmacological targeting of TMEM may be necessary, even after resection of the primary tumor, to suppress cancer cell dissemination.
KW - blood vessel
KW - breast cancer
KW - cancer cell dissemination
KW - lymph node
KW - lymphatic vessel
KW - tumor microenvironment of metastasis (TMEM)
UR - http://www.scopus.com/inward/record.url?scp=85095794224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095794224&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.571100
DO - 10.3389/fonc.2020.571100
M3 - Article
AN - SCOPUS:85095794224
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 571100
ER -